Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE Approach - PubMed
4 hours ago
- #obesity
- #GRADE approach
- #pharmacological management
- Obesity affects over 40% of US adults, with severe obesity increasing.
- Obesity is underdiagnosed and undertreated despite being a chronic disease.
- Barriers to treatment include socioeconomic disparities, limited clinician training, stigma, and restrictive reimbursement policies.
- FDA-approved obesity medications offer significant health benefits but are underutilized.
- A multidisciplinary panel used the GRADE approach to develop evidence-based guidance on obesity medications.
- Strong recommendations were made for bupropion-naltrexone, semaglutide, tirzepatide, and setmelanotide.
- Conditional recommendations were provided for other medications and specific obesity complications.
- Continuing obesity medications during weight maintenance received a strong recommendation.
- Expanding access, reducing stigma, and ensuring equitable coverage are essential for effective obesity care.
- Future priorities include improving affordability, addressing research gaps, and updating guidance as evidence evolves.